Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in overweight or obesity
NCT06207877Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing CagriSema with Placebo (2 arms). Primary endpoint: Relative change in energy intake during ad libitum lunch, evening meal and snackbox at 156 days. Started Feb 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06207877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207877.